Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: CON

Swetha Rani Kanduri; Juan Carlos Q Velez

doi:10.34067/KID.0003902021

Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: CON

Kidney360. 2021 Sep 17;3(5):803-805. doi: 10.34067/KID.0003902021. eCollection 2022 May 26.

Authors

Swetha Rani Kanduri¹, Juan Carlos Q Velez^{1

2}

Affiliations

¹ Department of Nephrology, Ochsner Clinic Foundation, New Orleans, Louisiana.
² Department of Nephrology, Ochsner Clinical School, Brisbane, Australia.

No abstract available

Keywords: CONS; acute interstitial nephritis; acute kidney injury; acute kidney injury and ICU nephrology; causality; debates; immune checkpoint inhibitors; immune-related adverse effects; rechallenge.

MeSH terms

Acute Kidney Injury* / chemically induced
Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Nivolumab / adverse effects

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Nivolumab